» Articles » PMID: 21271251

Biocompatibility of Implants: Lymphocyte/macrophage Interactions

Overview
Publisher Springer
Date 2011 Jan 29
PMID 21271251
Citations 75
Authors
Affiliations
Soon will be listed here.
Abstract

The monocyte-derived macrophage is recognized as a critical determinant in biocompatibility, but its appearance in the chronic inflammatory phase is accompanied by the presence of lymphocytes, which have been much less studied in this regard. Here, we first present an overview of the physiologic continuum comprising host reactions to the surgical implantation of biomaterial. Secondly, we describe our collective research efforts, which indicate that lymphocytes are additional and key cellular determinants of biocompatible outcome. Thus, bioengineering advances will require that lymphocyte responses be regarded as integral components of innate inflammatory and immune/immunotoxic cell interactions at sites of biomaterial implantation.

Citing Articles

Unraveling the Immune Web: Advances in SMI Capsular Fibrosis from Molecular Insights to Preclinical Breakthroughs.

Schoberleitner I, Faserl K, Lackner M, Coraca-Huber D, Augustin A, Imsirovic A Biomolecules. 2024; 14(11).

PMID: 39595609 PMC: 11592141. DOI: 10.3390/biom14111433.


A Co-Culture System for Studying Cellular Interactions in Vascular Disease.

Padmanaban A, Ganesan K, Ramkumar K Bioengineering (Basel). 2024; 11(11).

PMID: 39593750 PMC: 11591305. DOI: 10.3390/bioengineering11111090.


Advanced Immunomodulatory Biomaterials for Therapeutic Applications.

Park J, Kim D Adv Healthc Mater. 2024; 14(5):e2304496.

PMID: 38716543 PMC: 11834384. DOI: 10.1002/adhm.202304496.


CD4 and CD8 T cells reduce inflammation and promote bone healing in response to titanium implants.

Avery D, Morandini L, Sheakley L, Grabiec M, Olivares-Navarrete R Acta Biomater. 2024; 179:385-397.

PMID: 38554889 PMC: 11045310. DOI: 10.1016/j.actbio.2024.03.022.


Advancing CAR-based immunotherapies in solid tumors: CAR- macrophages and neutrophils.

Liang Y, Xu Q, Gao Q Front Immunol. 2023; 14:1291619.

PMID: 38090576 PMC: 10715261. DOI: 10.3389/fimmu.2023.1291619.


References
1.
Lodoen M, Lanier L . Natural killer cells as an initial defense against pathogens. Curr Opin Immunol. 2006; 18(4):391-8. PMC: 7127478. DOI: 10.1016/j.coi.2006.05.002. View

2.
Santana M, Rosenstein Y . What it takes to become an effector T cell: the process, the cells involved, and the mechanisms. J Cell Physiol. 2003; 195(3):392-401. DOI: 10.1002/jcp.10258. View

3.
Azzi A, Stocker A . Vitamin E: non-antioxidant roles. Prog Lipid Res. 2000; 39(3):231-55. DOI: 10.1016/s0163-7827(00)00006-0. View

4.
Zingoni A, Sornasse T, Cocks B, Tanaka Y, Santoni A, Lanier L . NK cell regulation of T cell-mediated responses. Mol Immunol. 2004; 42(4):451-4. DOI: 10.1016/j.molimm.2004.07.025. View

5.
Isomaki P, Clark J, Panesar M, Cope A . Pathways of T cell activation and terminal differentiation in chronic inflammation. Curr Drug Targets Inflamm Allergy. 2005; 4(3):287-93. DOI: 10.2174/1568010054022042. View